Post hoc analysis of TEMPO-2 (884 patients with minor stroke and occlusion): in those aged >80, tenecteplase vs standard care led to worse 90-day function (mRS 0–1 46.2% vs 59.8%) and more serious adverse events despite more recanalisation; no difference at ≤80.
Secondary analysisn = 884
Ganesh et al. Outcomes After Minor Ischemic Stroke in Older Patients Treated With IV Thrombolysis vs Standard of Care in the TEMPO-2 Trial